RekrutujeFaza III
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer…
Miasta: Bydgoszcz, Konin, Koszalin, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza I
An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered via the ThecaFlex DRx™ System (PIERRE-PK)
Miasta: Kraków, ŁódźWiek: od 0 latSponsor: Biogen Idec Research Limited
RekrutujeFaza III
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Miasta: Warszawa, ŁódźWiek: 18-64 latSponsor: Janssen Cilag International
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza II
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Miasta: Kraków, Legionowo, Radom, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Medica Scientia Innovation Research S.L.
RekrutujeFaza III
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Miasta: Bydgoszcz, Gdańsk, Konin, Lublin i 2 inne miastaWiek: od 18 latSponsor: OSE Immunotherapeutics
RekrutujeFaza I
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Miasta: Gdańsk, Kraków, Poznań, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Duke Street Bio Limited
RekrutujeFaza II
Assessment of the safety and effectiveness of vedolizumab induction therapy compared to standard infliximab therapy in pediatric patients with ulcerative colitis "VEDI-UC”
Miasta: Białystok, Gdańsk, Katowice, Lublin i 6 innych miastWiek: do 17.99 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka
RekrutujeFaza III
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0…
Miasta: Biała Podlaska, Koszalin, Lublin, Poznań i 3 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
W Polsce: Rekrutacja wstrzymanaNa świecie: RekrutujeFaza III
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Miasta: Bydgoszcz, Otwock, Prabuty, Tomaszów Mazowiecki i 1 inne miastoWiek: od 18 latSponsor: Daiichi Sankyo Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
Miasta: Warszawa, ŁódźWiek: do 64 latSponsor: Grin Therapeutics Inc.
RekrutujeFaza III
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced…
Miasta: Białystok, Bystra, Gdynia, Gliwice i 9 innych miastWiek: od 18 latSponsor: Amgen Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Miasta: Warszawa, ŁódźWiek: 18-64 latSponsor: Janssen - Cilag International
RekrutujeFaza II
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency
Miasta: Białystok, Gdańsk, Szczecin, Warszawa i 2 inne miastaWiek: do 17.99 latSponsor: Lumos Pharma Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Miasta: Gdańsk, Lublin, Wrocław, ŁódźWiek: od 18 latSponsor: Deuteroncology
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Miasta: Gdańsk, ŁódźWiek: do 64 latSponsor: Novartis Pharma AG
RekrutujeFaza III
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Miasta: Warszawa, ŁódźWiek: do 64 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in…
Miasta: Białystok, Gdańsk, Kraków, Warszawa i 2 inne miastaWiek: do 64 latSponsor: Bayer AG
RekrutujeFaza III
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Miasta: Gdańsk, Katowice, Kraków, Rzeszów i 4 inne miastaWiek: do 17.99 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza I/II
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Miasta: Konin, Poznań, Tomaszów Mazowiecki, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Stemline Therapeutics Inc.
RekrutujeFaza II
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Miasta: Katowice, Kraków, Szczecin, Warszawa i 2 inne miastaWiek: do 17.99 latSponsor: Arena Pharmaceuticals Inc.
RekrutujeFaza III
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Miasta: Kraków, Poznań, Warszawa, Wrocław i 1 inne miastoWiek: do 64 latSponsor: Sk Life Science Inc.
RekrutujeFaza II
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Miasta: Gdańsk, Olsztyn, Warszawa, ŁódźWiek: od 18 latSponsor: Synthekine Inc.
RekrutujeFaza II
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Miasta: Kraków, Warszawa, ŁódźWiek: do 17.99 latSponsor: Travere Therapeutics Inc.
RekrutujeFaza II/III
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Miasta: Warszawa, ŁódźWiek: do 17.99 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka
RekrutujeFaza III
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated…
Miasta: Olsztyn, Poznań, Rzeszów, Warszawa i 1 inne miastoWiek: od 18 latSponsor: AbbVie Deutschland GmbH & Co. KG
RekrutujeFaza III
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Miasta: Gdańsk, Katowice, Kraków, Rzeszów i 4 inne miastaWiek: do 17.99 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza I/II
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Miasta: Gliwice, Katowice, ŁódźWiek: od 18 latSponsor: BioInvent International AB
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects…
Miasta: Białystok, Kraków, ŁódźWiek: do 17.99 latSponsor: Amag Pharmaceuticals Inc.
RekrutujeFaza III
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include…
Miasta: Białystok, Brzeziny, Bydgoszcz, Gdańsk i 11 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
Rekrutacja wkrótceFaza II
A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinations in Adult Patients With TROP2 NMR-positive Non-small Cell Lung Cancer…
Miasta: Chęciny, Przemyśl, Sosnowiec, ŁódźWiek: od 18 latSponsor: AstraZeneca AB